Loncastuximab Tesirine in WM

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 17, 2022

Primary Completion Date

May 1, 2026

Study Completion Date

August 1, 2028

Conditions
Waldenstrom Macroglobulinemia
Interventions
DRUG

Loncastuximab Tesirine

Administered by intravenous infusion

DRUG

Dexamethasone

Taken orally or administered by intravenous infusion

Trial Locations (4)

55905

RECRUITING

Mayo Clinic, Rochester

98109

RECRUITING

Fred Hutch, Seattle

02115

RECRUITING

Dana Farber Cancer Institute, Boston

02215

RECRUITING

Beth Israel Deaconess Medical Center, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

ADC Therapeutics S.A.

INDUSTRY

lead

Shayna Sarosiek, MD

OTHER